Premium
Quantification of rimonabant (SR 141716A) in plasma using HPLC with UV detection
Author(s) -
Javors Martin A,
McMahon Lance R
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.5.a417-a
Subject(s) - rimonabant , chromatography , chemistry , high performance liquid chromatography , extraction (chemistry) , antagonist , cannabinoid receptor , receptor , biochemistry
The purpose of this study was to develop a method to quantify levels of the CB 1 antagonist rimonabant in plasma of rhesus monkeys and to correlate plasma rimonabant with its behavioral effects. The isocratic HPLC system included a mobile phase of 62% (v/v) acetonitrile:40% (v/v) 20 mM sodium phosphate (pH 6.7), flow rate of 1.5 ml/min, a Phenomenex Gemini C18 column (4.6 mm ID × 150 mm length, 5 μ) and UV absorbance detection at 214 nm. The retention time for rimonabant was 10.8 min. Blood samples were collected by standard phlebotomy procedures into EDTA tubes and plasma was prepared by centrifugation. Extraction of rimonabant spiked in plasma was performed using Bond‐Elut LRC Certify prep cartridges. The results show that extraction of rimonabant was constant and response was linear across plasma concentrations between 50 and 500 ng/mL. Extraction recovery of rimonabant was 82%, within and between day imprecision were <5% and <10%, respectively, and within and between day accuracy was >98%. Rimonabant was measured in monkey plasma over 24 h after i.v. injection of 3.2 mg/kg; peak concentrations were observed at 10 min and there was minimal detection at 24 h. The analytical assay described here provides a suitable procedure for multiple, within subject measurements of the CB 1 antagonist rimonabant that will serve as an adjunct to behavioral procedures in rhesus monkeys. Supported by USPHS grants DA15468 and DA19222